A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer

By sjmartinez • June 28, 2025

Lloyd MR, Chica-Parrado R, Weipert CM, Knepper TC, Podany EL, Napolitano F, Ye D, Lin CC, Uemoto Y, Liao J, Wegrzyn C, Walko CM, Ryan LY, Keenan JC, Medford AJ, Liu SA, Wulf GM, Clifton KK, Ma CX, Han HS, Zhang N, Ellisen LW, Bardia A, Arteaga CL, Hanker AB, Wander SA. A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer. EBioMedicine. 2025 Jun 26;118:105828. doi: 10.1016/j.ebiom.2025.105828. Epub ahead of print. PMID: 40578027.

Tags: CDK4/6 inhibitor, Hematology/Oncology, HR+ breast cancer, metastatic breast cancer, NF1 mutation, Precision medicine, Publications, Resistance mechanisms

Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement

Llovet JM, Mauro E, Rimassa L, Mazzaferro V, Pinter M, Kelley RK, Chan SL, Kulik L, Pillai A, Roberts L, Sangro B, Casanovas T, Kaplan[...]

Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1

Lim A, Peluso EM, Downs IA, Horwich BH, Velez-Velez MA, Lechner MG. Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome[...]

A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial)

Kirtane K, Niu J, Blumenschein G, Massarelli E, Hanna GJ, Lee S, Bishop MR, Konecny GE, Mao D, Zheng Y, Rodriguez K, Kim JJ, Williams[...]